Amalgamated Financial’s Sarepta Therapeutics SRPT Stock Holding History

Amalgamated Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.5M	Buy	+19,175	New	+$1.47M	0.01%	1016

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Amalgamated Financial's SRPT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Sarepta Therapeutics (SRPT) in Q1 2022: 19,175 shares worth $1.5M. The stake represents 0.01% of the portfolio and ranks #1016 among its holdings.

329 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

Amalgamated Financial held 19,175 shares of Sarepta Therapeutics worth $1.5M as of Q1 2022.
Sarepta Therapeutics was a new Amalgamated Financial position in Q1 2022.
Sarepta Therapeutics made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1016 holding.
329 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.